Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $9.8333.
BDTX has been the subject of several recent analyst reports. BTIG Research upped their price objective on shares of Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wall Street Zen downgraded shares of Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Jefferies Financial Group raised shares of Black Diamond Therapeutics to a “strong-buy” rating in a report on Thursday, April 23rd. TD Cowen reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a report on Friday, May 22nd. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of Black Diamond Therapeutics in a report on Friday, May 22nd.
Read Our Latest Analysis on BDTX
Institutional Trading of Black Diamond Therapeutics
Black Diamond Therapeutics Stock Up 5.7%
Shares of BDTX opened at $1.85 on Friday. The company’s fifty day moving average is $2.38 and its 200-day moving average is $2.42. Black Diamond Therapeutics has a 12 month low of $1.60 and a 12 month high of $4.94. The firm has a market cap of $106.01 million, a price-to-earnings ratio of -2.40 and a beta of 3.22.
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. As a group, research analysts predict that Black Diamond Therapeutics will post -0.6 earnings per share for the current fiscal year.
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.
The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
